Epithelial-Mesenchymal Transition (EMT) Markers

Thu, 08/18/2016 - 14:15


Epithelial-Mesenchymal Transition (EMT) is the trans-differentiation of stationary epithelial cells into motile mesenchymal cells. During EMT, epithelial cells lose their junctions and apical-basal polarity, reorganize their cytoskeleton, undergo a change in the signaling cascade that defines cell shape and reprograms gene expression. Collectively, these changes increase the motility of individual cells and enables the development of an invasive phenotype. At the molecular signaling level, EMT is regulated through several pathways which are triggered by TGF-beta, HGF, EGF, FGF, VEGF, Wnt, SHH, IL6, HIF1 alpha, and other proteins. At the transcription level, SNAI1/Snail, ZEB1/ZEB2 and basic helix-loop-helix transcription factors (bHLH) drive EMT progression. Accumulating evidence has established involvement of EMT in several biological processes including (but not limited to) embryonic and post-embryonic development, tissue regeneration/wound healing, stem cell homeostasis, and in pathophysiology of fibrosis and malignancies.

In line with the growth and expansion of this research area, there has been a growing need for high quality antibodies against established as well as new markers for EMT studies. Novus Biologicals offer a range of antibodies for Epithelial Phenotype Markers, Mesenchymal Phenotype (Stemness) Markers and other major EMT signaling players. Some of our most popular targets are:


Epithelial Markers

Mesenchymal Markers

Other Major EMT Players

Collagen IV alpha 1 

Alpha-SMA

beta-Catenin

Cytokeratin (pan)

Fibronectin

Cadherin-11

Desmoglein-3

N-Cadherin

GSK-3 beta

E-Cadherin

S100A4

MMP2

Laminin

Slug

SUMO2

MUC-1

Snail

Twist-1

Syndecan-1

Vimentin

ZEB1

Novus antibodies are rigorously validated in multiple species/applications, and for addressing the multiplexing needs, we provide antibodies in unconjugated as well as 21+ conjugated formats (custom conjugations also available). The validation data of some of the above mentioned targets is shown below:  

E-Cadherin Antibody

Vimentin antibody

E-Cadherin Antibody (7H12) [NBP2-19051]
ICC/IF staining of E-Cadherin protein in cultured human colon cancer spheres using NBP2-19051 with DyLight 488 conjugated secondary antibody (green). The nuclei of the cells were counterstained using DAPI (blue). Note the specific staining of E-Cadherin localized to the cell membranes of the cancer cells.

Vimentin Antibody (280618) [MAB2105]
ICC/IF staining of Vimentin in rat cortical stem cells using MAB2105 with NorthernLights™ 557-conjugated secondary antibody (red; Catalog # NL013) and counterstaining using DAPI (blue). Note the specific staining of Vimentin localized to the cytoskeleton.

ZEB1 Antibody

MMP-2 antibody

ZEB1 Antibody [NBP2-13159]
WB analysis of lysates from (1) HeLa, (2) COS7, (3) HepG2, and (4) Ntera-2 cells using rabbit polyclonal ZEB1 antibody. The signal was developed using HRP-conjugated secondary and ECL detection method. The antibody detected specific bands of ZEB1 in all of the tested cell lines with highest expression HeLa cells. 

MMP-2 Antibody [NB200-193]
IHC analysis of a FFPE tissue section of human hepatocellular carcinoma using at 1:400 dilution of MMP2 antibody with HRP-DAB detection method. Nuclei were counterstained using Hematoxylin and the antibody generated a diffused staining of MMP2 in the cytoplasm and the inter-cellular spaces of hepatic cancer cells.

Having trouble in generating high quality data in EMT and stemness experiments? Read through our scientific and technical answers to ~ 20 frequently asked questions on EMT/stemness signaling, markers, induction and troubleshooting: EMT & Stemness FAQs


Blog Topics


Archives